Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 11/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | TEK | Q02763 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530792 | 0.87 | AURKA (0.34) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL4533384 | 0.86 | MERTK (0.37) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL6751225 | 0.84 | AURKA (0.41) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL4527789 | 0.82 | AURKA (0.37) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL4530700 | 0.79 | AURKA (0.34) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL4521045 | 0.77 | KDM4E (0.44) | MERTKAURKAEGFRAURKBCHEK1 | |
| SCHEMBL14923147 | 0.76 | AURKA (0.34) | MERTKAURKAEGFRAURKBKDR | |
| SCHEMBL4519939 | 0.76 | AURKA (0.41) | AURKACHEK1KDRTEK | |
| SCHEMBL14923143 | 0.76 | AURKA (0.41) | AURKACHEK1KDRTEK | |
| SCHEMBL4519987 | 0.76 | CHEK1 (0.46) | MERTKAURKAEGFRAURKBCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183246-B2 | Acyclically substituted furopyrimidine derivatives and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318475-A1 | Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof | DPYD, PNPO, TPMT | MERTK 1999/4885AURKA 2909/4885EGFR 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.